I am a shareholder in PTX, NEU & IMU & CSL ... biotechs that I have a high level of conviction in.
I am so happy with the exciting news that dropped today by Acadia Pharma (NEU on Monday) about the FDA approval of Trofinetide on 10 March 2023. Great for the NZ & Aus biotech industry. Congratulations.
Here is a snippet from an announcement today:
In the image above look at the number of patient range: 6,000 to 9,000 in the USA.
Now look at the following recent PTX slides for PTX100:
Similar USA potential patient number
Question: Could PTX be the next NEU???
NEU market Cap before FDA Trofinetide approval on 10 March 2023: Approx A$990m. Monday potentially 1.5 times that or more
PTX Market Cap as at 10 March 2023: Approx A$95m. Huge difference.
PTX is several years behind NEU but if they continue to follow the science and progress with conviction, then there is no reason why PTX can't emulate the successful approval success of NEU.
Plenty of upside as long as PTX can remain supported & funded through to making this possibility a reality.
I am going to ride the journey with PTX.
GLTAHs
